Anti-EGFR Monoclonal Antibodies plus Chemotherapy in the First-Line Treatment of Advanced NSCLC: A Meta-Analysis

被引：0
|
作者：
Stock, Gustavo [1 ]
Aguiar, Pedro, Jr. [1 ]
Santoro, Ilka [1 ]
Tadokoro, Hakaru [1 ]
De Mello, Ramon [2 ]
Lopes, Gilberto [3 ]
机构：
[1] Univ Fed Sao Paulo, Sao Paulo, Brazil
[2] Univ Algarve, Faro, Portugal
[3] HCOR Canc Ctr, Sao Paulo, Brazil
来源：
JOURNAL OF THORACIC ONCOLOGY | 2017年 / 12卷 / 01期
关键词：
anti-EGFR; biomarker; Targeted therapy; Individual Medicine;
D O I：
10.1016/j.jtho.2016.11.360
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OA23.01
引用
收藏
页码：S333 / S334
页数：2
相关论文
共 50 条
  • [1] Anti-VEGF and Anti-EGFR Monoclonal Antibodies in the First-line Therapy for Metastatic Colorectal Cancer - A Meta-Analysis
    Zhou, Zheng
    Walsh, William V.
    Bathini, Venu G.
    Piperdi, Bilal
    CURRENT CANCER THERAPY REVIEWS, 2011, 7 (04) : 282 - 289
  • [2] Effect of RAS on anti-EGFR monoclonal antibodies plus 5-FU infusion-based chemotherapy in first-line treatment of metastatic colorectal cancer: A meta-analysis
    Zhou, Mingyi
    Yu, Ping
    Hou, Kazuo
    Jin, Bo
    Qu, Xiujuan
    Liu, Yunpeng
    Liu, Yunpeng
    Zhang, Jingdong
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [3] Anti-VEGF and anti-EGFR monoclonal antibodies (Mabs) in the first-line therapy for metastatic colorectal cancer: A meta-analysis
    Zhou, Z.
    Walsh, W. V.
    Bathini, V. G.
    Piperdi, B.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [4] Combination of EGFR-TKIs and Chemotherapy as First-Line Therapy for Advanced NSCLC: A Meta-Analysis
    OuYang, Pu-Yun
    Su, Zhen
    Mao, Yan-Ping
    Deng, Wuguo
    Xie, Fang-Yun
    PLOS ONE, 2013, 8 (11):
  • [5] The role of anti-EGFR agents in the first-line treatment of advanced esophago-gastric adenocarcinoma: a meta-analysis
    Kim, Bum Jun
    Kim, Jung Han
    Jang, Hyun Joo
    Kim, Hyeong Su
    ONCOTARGET, 2017, 8 (58) : 99033 - 99040
  • [6] Chemotherapy and Osimertinib Combination Should Not Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Lim, Sun Min
    Lee, Jii Bum
    Cho, Byoung Chul
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 376 - 379
  • [7] Chemotherapy and Osimertinib Combination Should Be the First-Line Treatment for All Advanced EGFR plus NSCLC
    Chen, Lanyi Nora
    Lee, Alexandria T. M.
    Nagasaka, Misako
    Ou, Sai-Hong Ignatius
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (03) : 380 - 384
  • [8] First-line anti-EGFR monoclonal antibodies in panRAS wild-type metastatic colorectal cancer: A systematic review and meta-analysis
    Pietrantonio, Filippo
    Cremolini, Chiara
    Petrelli, Fausto
    Di Bartolomeo, Maria
    Loupakis, Fotios
    Maggi, Claudia
    Antoniotti, Carlotta
    de Braud, Filippo
    Falcone, Alfredo
    Iacovelli, Roberto
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2015, 96 (01) : 156 - 166
  • [9] Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
    van Helden, E. J.
    van Oordt, C. W. Menke-van der Houven
    Heymans, M. W.
    Ket, J. C. F.
    van den Oord, R.
    Verheul, H. M. W.
    CANCER AND METASTASIS REVIEWS, 2017, 36 (02) : 395 - 406
  • [10] Optimal use of anti-EGFR monoclonal antibodies for patients with advanced colorectal cancer: a meta-analysis
    E. J. van Helden
    C. W. Menke-van der Houven van Oordt
    M. W. Heymans
    J. C. F. Ket
    R. van den Oord
    H. M. W. Verheul
    Cancer and Metastasis Reviews, 2017, 36 : 395 - 406
12345